Experimental studies suggest empagliflozin directly inhibits the NHE1 exchanger and SGLT1 in cardiomyocytes [32], reducing sodium content, improving mitochondrial function, and decreasing oxidative stress, which are additional mechanisms proposed for arrhythmia reduction. Here, SLC5A1 is linked to cardiac arrhythmia.